PIP

PIP (GCDFP-15/prolactin-inducible protein) is a small secreted glycoprotein that serves as a marker of apocrine epithelial differentiation and functions extracellularly as a multivalent binding protein with roles in secretion, immune modulation, and aquaporin trafficking (PMID:6130702, PMID:7840903, PMID:34440877). It is synthesized through the secretory pathway, stored in Golgi vesicles and cytoplasmic granules, packaged into apical vacuoles, and released by exocytosis from apocrine-type epithelial cells; correct secretory processing via its signal peptide is required for proper folding and solubility (PMID:6205595, PMID:10504398). Its expression is controlled at the level of transcription: androgen receptor signaling (DHT), prolactin, glucocorticoids, and the cytokines IL-4 and IL-13 each upregulate PIP, whereas estradiol represses it and antagonizes androgen- and glucocorticoid-driven induction (PMID:1955075, PMID:2725533, PMID:8865161, PMID:10402478). Extracellularly PIP binds actin, fibrinogen, and bacterial cell walls, and binds CD4 on lymphocytes where it blocks CD4-mediated T-cell programmed death (PMID:7840903, PMID:10504398). PIP also directly binds the water channel AQP5 through the AQP5 C-terminus and its own N-terminal region (one PIP per AQP5 tetramer), controlling AQP5 trafficking to the apical membrane in salivary glands (PMID:34440877). In a pathological context, PIP acts downstream of the transcription factor Slug as an extracellular matrix protein that drives pulmonary arterial smooth muscle cell proliferation in pulmonary hypertension (PMID:31468711).

1. 1983 Medium

   Established where PIP/GCDFP-15 is expressed, defining it as a marker of apocrine differentiation across diverse epithelia.

   Evidence Immunoperoxidase IHC across normal and tumor tissues

   PMID:6130702

   Open questions at the time

   • Localization alone did not define molecular function
   • No mechanism for tissue-restricted expression
2. 1984 High

   Resolved the subcellular route of PIP, showing it traverses the regulated secretory pathway rather than acting intracellularly.

   Evidence Colloidal gold immunoelectron microscopy in metaplastic apocrine breast epithelium

   PMID:6205595

   Open questions at the time

   • Did not identify extracellular binding partners or function of secreted protein
3. 1989 High

   Defined the hormonal logic of PIP regulation, showing androgens and glucocorticoids induce while estrogens repress and antagonize that induction.

   Evidence Northern blot, ELISA/RIA, and antiestrogen competition in ZR-75-1 breast cancer cells

   PMID:2725533

   Open questions at the time

   • Did not map cis-regulatory elements or confirm direct receptor binding to the promoter
4. 1991 High

   Determined that hormonal control of PIP operates at transcription rather than RNA stability, localizing regulation to the gene level.

   Evidence Gene cloning and nuclear run-on transcription assays with PIP genomic fragments

   PMID:1955075

   Open questions at the time

   • Specific promoter elements and bound factors not identified
5. 1994 Medium

   Identified PIP as a multivalent extracellular binding protein, linking it to cytoskeletal/coagulation ligands and mucosal bacteria.

   Evidence Immunochemical identity assays and in vitro binding to actin, fibrinogen, and Streptococcus salivarius cell walls

   PMID:7840903

   Open questions at the time

   • Physiological relevance of actin/fibrinogen binding noted as unclear by authors
   • No structural basis for the interactions
6. 1996 Medium

   Extended PIP regulation to cytokine signaling, showing IL-4 and IL-13 induce PIP via an apparently shared pathway additive to steroid hormone induction.

   Evidence Northern blot, RIA/ELISA, and additivity/dose-response in ZR-75-1 and T-47D cells

   PMID:8865161

   Open questions at the time

   • Shared IL-4/IL-13 signaling pathway inferred from additivity, not directly mapped
7. 1999 Medium

   Provided functional evidence that secreted PIP binds CD4 and inhibits CD4-mediated T-cell apoptosis, and that secretory processing is required for proper folding.

   Evidence Recombinant expression in HeLa and P. pastoris; CD4 binding and apoptosis inhibition assays

   PMID:10504398

   Open questions at the time

   • CD4-binding interface not mapped
   • In vivo relevance of T-cell apoptosis inhibition not established
8. 1999 Medium

   Confirmed the androgen receptor as a regulator of PIP using antiandrogen antagonism in AR-positive cells.

   Evidence RT-PCR/Northern blot, secretion measurement, and antiandrogen competition in MFM-223 and ZR-75-1 cells

   PMID:10402478

   Open questions at the time

   • Direct AR binding to PIP regulatory DNA not demonstrated
9. 2019 Medium

   Placed PIP in a pathological signaling axis, acting downstream of Slug as an extracellular matrix protein driving smooth muscle proliferation in pulmonary hypertension.

   Evidence IHC in human PF-PH tissue and rat model, Slug inhibition in vivo, PASMC proliferation assays

   PMID:31468711

   Open questions at the time

   • Receptor/signaling mechanism for PASMC proliferation not identified
   • Single lab, one disease context
10. 2021 Medium

    Defined a direct molecular function for PIP as an AQP5 trafficking regulator, mapping the interaction and showing functional consequences for apical membrane localization.

    Evidence Co-IP/pulldown in vitro and in mouse tissue, domain mapping, IHC in PIP-knockout mice and Sjögren's patient salivary glands

    PMID:34440877

    Open questions at the time

    • Mechanism by which PIP promotes AQP5 trafficking unresolved
    • Stoichiometry-to-function relationship not fully defined

• How PIP's diverse extracellular binding activities (CD4, actin, fibrinogen, AQP5, ECM) integrate into a unified physiological role, and the structural basis for its multivalent binding, remain unresolved.
• No structural model linking distinct binding partners
• No single in vivo phenotype unifying its secretory, immune, and trafficking roles